UCLA Scientists Identify Possible Markers For EGFR-Inhibitor Response in Glioblastomas | GenomeWeb

The EGFR pathway is common to a variety of cancers, and a project led by researchers at the University of California, Los Angeles, is working out how to find patients with glioblastomas who will respond to EGFR inhibitors, such as Tarceva, a product of OSI Pharmaceuticals, Pfizer, and Genentech; and Iressa, made by AstraZeneca.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.